drugset / Trial / NCT07225556

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT07225556 ↗

Phase 1 Active not recruiting 84 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.

Timeline

Start
2025-11-18
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LY4167586 Unknown — Subcutaneous

Indications